Confirmation of Reported Aspirin Use in Community Studies: Utility of Serum Thromboxane B2 Measurement. (May 2014)

• Record Type: Journal Article
• Authors: Zantek, Nicole Dodge; Luepker, Russell V.; Duval, Sue; Miller, Karen; Oldenburg, Niki; Hirsch, Alan T.
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 20:Number 4(2014:May)
• Page Start: 385
• Page End: 392
• Publication Date: 2014-05
• Subjects: aspirin -- thromboxane B2 -- compliance -- cardiovascular prevention -- nonsteroidal anti-inflammatory drug -- NSAID; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/1076029613486537
• Languages: English
• ISSNs: 1076-0296

Abstract

Aspirin (ASA) is recommended for the prevention of cardiovascular disease; however, the compliance is low. Reported use may not reflect actual use. Serum thromboxane B2 (STxB2 ) measurement was evaluated to validate reported ASA use. Males aged 45 to 79 years and females aged 55 to 79 years completed a survey and STxB2 measurement (Thromboxane B2 EIA Kit; Cayman Chemical, Ann Arbor, Michigan). The 107 patients were grouped by use of ASA (56 ASA+ and 51 ASA−) and possible interfering medications (INT) such as nonsteroidal anti-inflammatory drugs. The STxB2 levels (ng/mL) were significantly lower in ASA users: ASA+ INT− 3.0 (0.7, 8.4), ASA+ INT+ 2.0 (0.8, 4.9), ASA− INT+ 176 (75, 390), and ASA− INT− 271 (199, 366). The INT use did not cause a significant difference in STxB2 levels. A STxB2 cut point of 25 ng/mL had high sensitivity (94.1%) and specificity (91.1%) for ASA use. The STxB2 was a reliable marker of ASA use and could be used to confirm ASA exposure in population-based health studies.